

University of Groningen

Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction

Artola Arita, Vicente; Santema, Bernadet T; De With, Ruben R; Nguyen, Bao-Oanh; Linz, Dominik; Schotten, Ulrich; Van Gelder, Isabelle C; Crijns, Harry J G M; Voors, Adriaan A; Rienstra, Michiel

Published in:
 American Heart Journal

DOI:
[10.1016/j.ahj.2021.10.183](https://doi.org/10.1016/j.ahj.2021.10.183)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Artola Arita, V., Santema, B. T., De With, R. R., Nguyen, B-O., Linz, D., Schotten, U., Van Gelder, I. C., Crijns, H. J. G. M., Voors, A. A., & Rienstra, M. (2022). Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study. *American Heart Journal*, 244, 36-41. <https://doi.org/10.1016/j.ahj.2021.10.183>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: Data from the AF-RISK study



Vicente Artola Arita, MD^a, Bernadet T. Santema, MD^a, Ruben R. De With, MD^a, Bao-Oanh Nguyen, MD^a, Dominik Linz, MD, PhD^{b,c,d,e,f}, Ulrich Schotten, MD, PhD^{c,d}, Isabelle C. Van Gelder, MD, PhD^a, Harry JGM. Crijns, MD, PhD^{b,c}, Adriaan A. Voors, MD, PhD^a, and Michiel Rienstra, MD, PhD^a *Maastricht*

Abstract Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are 2 cardiovascular conditions that often coexist. Strain phases of both the left and right atria are more impaired in paroxysmal AF patients with HFpEF than those without HFpEF in spite of comparable global longitudinal strain of the left ventricle. Atrial function may differentiate paroxysmal AF patients with HFpEF from those without HFpEF. (Am Heart J 2022;244:36–41.)

Keywords: Atrial fibrillation; Heart failure with preserved ejection fraction; Echocardiography; Left atrial function; Right atrial function; Speckle-tracking echocardiography

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are 2 cardiovascular conditions that often coexist. Both conditions are associated with aging, hypertension, obesity, and sleep apnea.^{1, 2} The presence of 1 of both conditions leads to an increased risk of the other. However, the overlap in symptoms, biomarker profile, and echocardiographic changes hinder the diagnosis of underlying HFpEF in patients with AF and suggests that both conditions might reflect similar remodeling processes in the heart.^{1, 2} The aim of this study was therefore to assess cardiac remodeling in AF patients with vs without concomitant HFpEF by transthoracic echocardiography, focusing on atrial dimension and speckle tracking of the left and right atria.

We included patients from the identification of a risk profile to guide atrial fibrillation therapy study (AF-RISK), a prospective, observational, multicenter study

(NCT01510210).³ In brief, inclusion criteria were patients aged ≥ 18 years, with paroxysmal AF (total AF history < 2 years, or total AF history < 3 years in case of ≤ 2 AF episodes of ≤ 48 hours per month terminating spontaneously) or persistent AF (total AF history < 2 years, and total persistent AF duration > 7 days and < 1 year). Exclusion criteria were patients with history of heart failure > 3 years, severe valvular disease, acute coronary syndrome < 1 month, post-operative AF or history of pulmonary vein isolation. For this subanalysis, 287 patients had paroxysmal AF, had a left ventricular ejection fraction (LVEF) $\geq 50\%$, were in SR (sinus rhythm) at the moment of performing echocardiography and blood sampling (Supplementary figure S-1). The diagnosis of HFpEF was based on the 2016 ESC heart failure guidelines, including symptoms and signs heart failure (dyspnea and fatigue, equivalent to NYHA \geq II) or history of HF hospitalization and N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥ 125 pg/ml, and 1 of the following echocardiographic measures: left atrium volume index (LAVI) > 34 ml/m², left ventricular mass index ≥ 115 g/m² for men and ≥ 95 g/m² for women, average E/e' ≥ 13 cm/s and average e' < 9 cm/s.⁴ Due to imbalances in age and sex between AF patients with HFpEF in comparison to those without HFpEF, patients were selected using propensity score matching by nearest neighbor. A 1:1 ratio created balanced differences in age and sex resulting in two groups: 1) AF with HFpEF ($n = 60$) and 2) AF without HFpEF ($n = 60$). A sensitivity analysis was performed in pa-

From the ^aDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands, ^bDepartment of Cardiology, Maastricht University Medical Centre +, Maastricht, The Netherlands, ^cCardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands, ^dDepartment of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands, ^eCentre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia, ^fDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Submitted March 16, 2021; accepted October 2, 2021

Reprint requests: Michiel Rienstra, MD, PhD, Department of Cardiology, University of Groningen, University Medical Centre Groningen, P.O. Box 30.001, GR 9700, The Netherlands.

E-mail address: m.rienstra@umcg.nl.

0002-8703

© 2021 Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.ahj.2021.10.183>

Abbreviation

ACE	Angiotensin-converting enzyme
AAD	Anti-arrhythmic drug
AF	Atrial fibrillation
BMI	Body mass index
COPD	Chronic obstructive pulmonary disease
ECV	Electrical cardioversion
EHRA	European heart rhythm association symptom classification
GLS	Global longitudinal strain
GDF-15	Chronic obstructive pulmonary disease
HF _p EF	Heart failure with preserved ejection fraction
AF-RISK	Identification of a risk profile to guide atrial fibrillation therapy study
LAVI	Left atrium volume index
LVEF	Left ventricular ejection fraction
NT-proBNP	n-terminal pro-b-type natriuretic peptide
SR	Sinus rhythm

tients with cutoff of NT-proBNP \geq 400pg/ml into the HFpEF definition.⁵ This work was supported by the Dutch Heart Foundation (NHS2010B233). This project received funding from European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie [agreement 754425].

Atrial function was determined by speckle tracking as it is less affected by loading conditions in comparison to volumetric methods.⁶ Reservoir, conduit and contraction strain of both atria was performed in apical four-chamber view by manually selecting endocardial borders from 1 cardiac cycle R-R gated (GE, EchoPac BT12). Tracking was manually adjusted for accuracy if needed. An independent observer, blinded to results, measured 10% of the strains to calculate inter-observer reliability. The average intraclass correlation coefficient of strain measures was 0.831, using average consistency two way random effects method. Associations of clinical and echocardiographic characteristics were tested for collinearity and by multivariable logistic regression analyses. LAVI, LV mass index and NT-proBNP were excluded from multivariable analysis since these markers were part of the HFpEF diagnostic criteria. A two-tailed *P*-value of $<.05$ was considered statistically significant. The study was performed in accordance with the Declaration of Helsinki and after local research ethics committee approval.

Patients with paroxysmal AF and concomitant HFpEF had more often beta-blocker and angiotensin-converting enzyme (ACE) inhibitors medication, had more often impaired strain phases of both the left and right atria as compared to those without HFpEF, and comparable time of AF diagnosis, AF burden, global longitudinal strain (GLS) of the left ventricle and LVEF (Table I) (Figure 1). In multivariable analyses including age, sex, use of ACE inhibitor and beta-blockers, LA reservoir and contraction decrease was associated with presence of HFpEF (OR per 5% decrease in LA reservoir 1.39, 95% CI 1.11 - 1.81, *P* = .008; OR per 5% decrease in LA contraction 1.96, 95% CI 1.26 - 3.33, *P* = .006) (Table II). LA reservoir and contraction phases were not placed in the same model due to collinearity (Supplementary figure S-2). LA reservoir and contraction were not correlated with LAVI in AF patients with concomitant HFpEF and moderately correlated in patients with AF (Supplementary table S-1). Similar results were observed in a sensitivity analysis of AF patients with HFpEF patients classified by a cutoff of NT-proBNP \geq 400pg/ml (Supplementary table S-3 and figure S-2)

Our results show that atrial function discriminates AF patients with HFpEF from those without HFpEF. In patients with AF, a more impaired structure and function of the left and right atria were associated with concomitant HFpEF, whereas ventricular function, reflected by GLS and LVEF, was comparable. LAVI was a criteria to classify patients with HFpEF and could therefore explain decrease in LA strain⁷; however, LA strains were not correlated with LAVI in our study. Our results are in accordance to previous studies suggesting LA strains as markers for improving the diagnosis of HFpEF.⁸ Kabbah et al found that LA reservoir and, followed by, LA contraction were associated with the probability of HFpEF in patients with paroxysmal AF and dyspnea, using two scores, H₂FPEF and HFA-PEFF.⁹ It has been shown that contraction function is reduced in advanced stages of AF,¹⁰ however in this study AF burden and time of AF history in both groups were comparable, possibly attributing the differences to having concomitant HFpEF. Even though we could only speculate about the explanations for these results, HFpEF plausible mechanisms imply higher cardiac energy consumption and production of reactive oxygen species;¹¹ the latter have been associated with decreased atrial myocardial energetics more than in the ventricles, predominantly in the LA.¹² This could increase remodeling of the atria in AF patients with concomitant HFpEF.

This analysis has limitations since the results are based on *post hoc* analyses and classification of HFpEF was performed after inclusion. The AFRISK study had already

Table 1. Clinical characteristics and echocardiographic measurements


Characteristic	Total population (n = 120)	AF with HFpEF (n = 60)	AF without HFpEF (n = 60)	P-value
Age(ys)	65±8	66±8	65±8	.807
Women %	58 (48)	31 (52)	27 (45)	.584
Diagnosis of AF(months)	7(2-20)	10(2-23)	4(2-15)	.142
Percentage AF %				.293
<5	97 (87)	46 (82)	51 (91)	
5 – 50	10(9)	6(11)	4(7)	
>50	5(4)	4 (7.1)	1(2)	
Hypertension %	107 (90)	57 (95)	50 (83)	.078
Diabetes mellitus %	17 (14)	7(12)	10 (17)	.601
Coronary artery disease %	8(7)	6(10)	2(3)	.272
Peripheral artery disease %	7(6)	2(3)	5(8)	.436
Stroke or TIA %	6(5)	3(5)	3(5)	.000
COPD %	9(8)	5(8)	4(7)	.000
BMI(kg/m ²)	27±4	28±4	26±4	.129
Obesity(BMI>30) %	30 (25)	18 (30)	12 (20)	.292
CHA ₂ DS ₂ -VASc score*	2.2±1.4	2.5±1.4	2.0±1.3	.061
Comorbidities†	2.5±1.2	2.7±1.2	2.4±1.2	.150
Fatigue	110 (92)	57 (95)	53 (88)	.322
Dyspnea	63 (53)	29 (48)	34 (58)	.405
EHRA class % I II III				.681
	30 (25)	13 (22)	17 (28)	
	68 (57)	36 (60)	32 (53)	
	22 (18)	11 (18)	11 (18)	
Medications				
β-Blocker %	82 (68)	48 (80)	34 (57)	.011
Verapamil/Diltiazem %	10(8)	6(10)	4(7)	.741
Digoxin %	4(3)	4(7)	0 (0)	.127
ACE-inhibitor %	40 (33)	27 (45)	13 (22)	.012
Anticoagulant %	81 (68)	45 (75)	36 (60)	.119
Class Ic AAD %	7(6)	4(7)	3(5)	.000
Class III AAD %	8(7)	5(8)	3(5)	.714
Previous ECV %	29 (24)	18 (30)	11 (18)	.201
Biomarkers				
NTproBNP (pg/ml)	189 (93 – 324)	268 (190 – 464)	87 (59 – 159)	<.001
GDF15 pg/ml	1033 (821-1422)	1141 (854 – 1480)	1002 (780 – 1339)	.287
Troponin-T pg/ml	6.4 (4.3 – 9.9)	6.9 (3.7 – 11.2)	6.1 (4.7 – 7.7)	.271
Echocardiography				
LAVI(mL/m ²)	35±10	40±8	29±8	<.001
RAVI(mL/m ²)	36±12	39±12	33±12	.013
LV ejection fraction(%)	58±3	57±3	58±3	.168
LV mass index(g/m ²)	86±21	89±22	82±21	.087
e'	8.8±1.9	8.8±1.9	8.8±2.0	.879
E/A ratio	1.0 (0.9 – 1.3)	1.1(0.9 – 1.3)	1.0 (0.8 – 1.2)	.078
E/e'	7.7 (6.6 – 9.8)	8.8(6.9 – 10.3)	7.2 (6.2 – 8.6)	.004
Left atrial strain(%)				
Reservoir	30.1±12.5	26.8±11.1	33.8±12.9	.003
Conduit	16.0± 7.7	14.7±6.7	17.4±8.6	.066
Contraction	14.1± 7.0	12.1±6.5	16.3±7.0	.001
Right atrial strain(%)				
Reservoir	41.6±13.5	39.4±12.5	43.7±14.2	.136
Conduit	22.5±9.3	22.2±7.8	22.9±10.6	.718
Contraction	19.1±7.8	17.3±7.6	20.9±7.7	.031
GLS (%)	-19.3±3.2	-18.9±3.4	-19.7±3.1	.212

ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECV, electrical cardioversion; GDF-15, growth differentiation factor 15; EHRA, European Heart Rhythm Association symptom classification; HFpEF, heart failure with preserved ejection fraction; LAVI, left atrial volume index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TIA, transient ischemic attack.

* The CHA₂DS₂-VASc score assesses thromboembolic risk. C, congestive heart failure/LV dysfunction; H, hypertension; A2, age ≥ 75 years; D, diabetes mellitus; S2, stroke/transient ischaemic attack/systemic embolism; V, vascular disease; A, age 65–74 years; Sc, sex category (female sex).

† The number of comorbidities was calculated by awarding a point for hypertension, age > 65 years, diabetes, coronary artery disease, body mass index > 25, kidney dysfunction, and moderate or severe mitral valve regurgitation.

Figure



Strain phases distribution of both left and right atria in patients with paroxysmal AF with HFpEF in comparison to those without HFpEF. Y axis expresses percentage of deformation measure by 2D speckle tracking by transthoracic echocardiography. Point within the graph expresses mean and lines determine standard deviation.

Table II. Predictors of heart failure with preserved ejection fraction in patients with atrial fibrillation

	OR	CI 95%	P
LA reservoir	1.38	1.14 – 1.71	.002
LA contraction	1.89	1.33 – 2.85	<.001
RA contraction	1.57	1.13 – 2.30	.012
LA reservoir +RA contraction	1.391.37	1.11 – 1.810.95 – 2.05	.008.108
LA contraction +RA contraction	1.961.36	1.26 – 3.330.94 – 2.06	.006.122

All models included age, sex, use of ACE inhibitor, use of beta-blockers
Results are shown as 5% reduction per strain phase
LA, Left atria; RA, right atria

small inclusion of patients and propensity score matching generated even smaller comparison groups. These results were performed in a population with paroxysmal AF and cannot be generalized to other forms of AF. Given the transversal analysis of the data, it cannot be determined whether HFpEF set the stage for AF nor inversely. Furthermore, the associations found might be affected by residual confounding. Echocardiographic B-line were not measured which could have provided insights into the congestive state in AF patients with HFpEF. These findings encourage the need for well phenotyped AF with and without HFpEF cohorts to further understand atrial remodeling processes and underlying AF substrate.

In conclusion, in patients with paroxysmal AF, more impaired strain phases of the left and right atria were associated with concomitant HFpEF, whereas ventricular function, reflected by LVEF and GLS, did not differ.

The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. J.G.L.M.L. has a consultancy agreement with Medtronic. A.A.V reports receiving consulting fees from Amgen, AstraZeneca, Cytokinetics, MyoKardia, Novartis, and Servier, and grant support and consulting fees from Boehringer Ingelheim and Roche Diagnostics.

Conflict of interest

J.G.L.M.L. has a consultancy agreement with Medtronic. A.A.V reports receiving consulting fees from Amgen, AstraZeneca, Cytokinetics, MyoKardia, Novartis, and Servier, and grant support and consulting fees from Boehringer Ingelheim and Roche Diagnostics.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.ahj.2021.10.183](https://doi.org/10.1016/j.ahj.2021.10.183).

References

- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS). *Eur Heart J* 2021;42:373–98.
- Kotecha D, Lam CS, Van Veldhuisen DJ, et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. *J Am Coll Cardiol* 2016;68:2217–28.
- De With RR, Marcos EG, Dudink EAMP, et al. Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. *Europace* 2020;22:352–60.
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129–200.
- Parkash R, Wells G, Rouleau J, et al. A randomized ablation-based atrial fibrillation rhythm control v rate control trial in patients with heart failure and high burden atrial fibrillation: the RAFT-AF trial rationale and design. *Am Heart J* 2021;234:90–100.
- Thomas L, Marwick TH, Popescu BA, et al. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state-of-the-art review. *J Am Coll Cardiol* 2019;73:1961–77.
- Gan GCH, Ferh A, Boyd A, et al. Left atrial function: evaluation by strain analysis. *Cardiovasc Diagn Ther* 2018;8:29–46.
- Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2016;17:1321–60.
- Katbeh A, De Potter T, Geelen P, et al. Heart failure with preserved ejection fraction or non-cardiac dyspnea in paroxysmal atrial fibrillation: the role of left atrial strain. *Int J Cardiol* 2021;323:161–7.

10. Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. *Circulation* 2001;103:691–8.
11. Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. *Eur Heart J* 2018;39:2780–92.
12. Ozcan C, Li Z, Kim G, et al. Molecular mechanism of the association between atrial fibrillation and heart failure includes energy metabolic dysregulation due to mitochondrial dysfunction. *J Card Fail* 2019;25:911–20.